SYS-CON MEDIA Authors: Kevin Benedict, Gilad Parann-Nissany

News Feed Item

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Provectus Biopharmaceuticals, Inc. to Contact the Firm

NEW YORK, NY -- (Marketwired) -- 05/30/14 -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company") (NYSE: PVCT) of the July 28, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Provectus and certain executives.

A complaint has been filed on behalf of all persons who purchased Provectus securities between December 17, 2013 and May 22, 2014, inclusive (the "Class Period") in the Middle District of Tennessee.

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) contrary to the Company's representations, preparations were not underway for a Phase 3 study for Provectus's oncology drug PV-10; (ii) the Company improperly referred to PV-10 as obtaining a Breakthrough Therapy Designation ("BTD") for the treatment of melanoma, and implied that securing that status was inevitable; and (iii) the Company used the services of paid stock promoters.

On January 23, 2014, the website www.thestreet.com published an article alleging that Provectus has caused the price of its stock to be artificially inflated by making false representations regarding the commencement of Phase 3 trials. On this new, the Company's stock declined $3.35 per share, or over 64%, to close at $1.87 per share on January 23, 2014.

Then, on May 20, 2014, the Company updated its website to change the description of PV-10 from a "breakthrough" drug for skin cancer to "An investigational Drug for Cancer," as well as to indicate that it was still awaiting BTD designation by the FDA. Following this news, the Company's stock declined $0.31 per share, or over 10%, to close at $2.70 per share on May 20, 2014.

The following day, on May 21, 2014, the website www.seekingalpha.com published an article suggesting that Provectus is connected with stock promoters that improperly marketed the Company's stock to unsophisticated retail investors, thus artificially inflating the price of the Company's shares. Provectus subsequently denied any affiliation with stock promoters, but on that day the Company's stock declined $0.46 per share, or over 17%, to close at $2.24.

Request more information now by clicking here: www.faruqilaw.com/PVCT. There is no cost or obligation to you.

Take Action

If you invested in Provectus stock or options between December 17, 2013 and May 22, 2014 and would like to discuss your legal rights, visit www.faruqilaw.com/PVCT. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding Provectus's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Email Contact
Francis McConville, Esq.
Email Contact
Telephone: (877) 247-4292 or (212) 983-9330

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.